Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Cytometry. Part B, Clinical Cytometry|October 2, 2019
Flow cytometric features of incidental indolent T lymphoblastic proliferationsJonathan R Fromm, Kerstin L Edlefsen, Sindhu Cherian, et al.
The American Journal of Dermatopathology|May 10, 2011
Flow cytometric evaluation of skin biopsies for mycosis fungoidesChris H Jokinen, Jonathan R Fromm, Zsolt B Argenyi, et al.
American Journal of Clinical Pathology|July 26, 2005
Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasiaSteven J Kussick, Jonathan R Fromm, Anthony Rossini, et al.
Cancer Cytopathology|July 1, 2022
Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypiaDavid C Gajzer, Youley Tjendra, Darcy A Kerr, et al.
American Journal of Clinical Pathology|June 10, 2026
CD48 expression in T-lymphoblastic leukemia/lymphoma and mature T-cell neoplasms: role in detecting measurable residual disease and potential confounders, a single-institution retrospective reviewAlireza Torabi, Jonathan R Fromm, Russell Dorer, et al.
Cytometry. Part B, Clinical Cytometry|November 13, 2018
Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1Yi Zhou, Andres Moon, Eric Hoyle, et al.
Genes, Chromosomes & Cancer|December 10, 2015
Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphomaStephen J Salipante, Andrew Adey, Anju Thomas, et al.
American Journal of Clinical Pathology|August 31, 2021
Clinicopathologic Findings in Patients With Initial Diagnosis of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) in Colorectal MucosaLorinda A Soma, Stephen D Smith, Prathima Reddy, et al.
Molecular Cancer Therapeutics|August 11, 2021
Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic LeukemiaAnlai Wang, Zhili Song, Gang Zheng, et al.
Blood Advances|July 22, 2020
Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemiaRyan D Cassaday, Kelsey-Leigh A Garcia, Jonathan R Fromm, et al.
Pageof 9